LRMR
Larimar Therapeutics, Inc.
$3.40
-5.29%
$353.2M
No data for this timeframe.
Vol
Market Cap$353.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders50 funds
Inst. Value$113.5M
Inst. Activity18 buys / 8 sells
Insider Activity4B / 0S
Insider Net $$6.0M
Reddit Sentiment69° Warm
SEC Reports5
Press Releases1
Recent Activity
Jun 10, 2026
short_volume
Short Volume: LRMR — 57.6% short (0.6M / 1.1M)
Short: 629,783 | Exempt: 8,000 | TRF Vol: 1,093,669 | Short Ratio: 57.6% | Off-exchange volume (dark
May 19, 2026
Insider
THOMAS FRANK E was granted 55,150 shares
Director
May 19, 2026
Insider
Hamilton Thomas Edward was granted 55,150 shares
Director
May 19, 2026
Insider
Truitt Joseph was granted 55,150 shares
Director
May 14, 2026
SEC
Larimar Therapeutics reported Q1 2026 net loss of $29.6M ($0.31/share), roughly in line with the $29.3M loss in Q1 2025,
8-K — Impact 7/10
May 14, 2026
SEC
Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consensus of -$0.57 by 45.6%, with no revenue. The company
PRESS-RELEASE — Impact 7/10
Mar 3, 2026
SEC
Four insiders at Larimar Therapeutics collectively purchased $6.07 million in shares over a single day at $5 per share,
CLUSTER — Impact 8/10
Inst.
DRIEHAUS CAPITAL MANAGEMENT LLC — DOUBLED
2,934,399 shares ($13.2M)
Price Targets
$15.11
+344.4% upside
Strong Buy
Current $3.40
Low $7.00
Median $13.00
High $26.00
9 analysts
$7.00
$26.00
Analyst Ratings
8Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | JP Morgan | INITIATE | Overweight |
| May 18, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Mar 20, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Mar 3, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Feb 25, 2026 | Citigroup | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.38 ▲ +17.2% | $-0.48 — $-0.34 | 7% YoY | 6 |
| Next Q | $-0.43 ▲ +4.0% | $-0.51 — $-0.35 | 30% YoY | 6 |
| Current FY | $-1.62 ▲ +23.4% | $-1.82 — $-1.43 | 29% YoY | 6 |
| Next FY | $-1.23 ▲ +25.7% | $-2.35 — $-0.16 | 24% YoY | 6 |
Latest Reports
BULLISH
8-K
7/10
Larimar Therapeutics reported Q1 2026 net loss of $29.6M ($0.31/share), roughly in line with the $29.3M loss in Q1 2025,
May 14, 2026
BULLISH
PRESS-RELEASE
7/10
Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consensus of -$0.57 by 45.6%, with no revenue. The company
May 14, 2026
MIXED
Press
7/10
Larimar Therapeutics reported Q4 and full-year 2025 financial results, highlighted by Breakthrough Therapy Designation f
Mar 19, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $16.9M | — |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $13.2M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $12.9M | — |
| GOLDMAN SACHS GROUP INC | $7.0M | — |
| RTW INVESTMENTS, LP | $6.8M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 19, 2026 | THOMAS FRANK | A | $0.00 |
| May 19, 2026 | Hamilton Thomas | A | $0.00 |
| May 19, 2026 | Truitt Joseph | A | $0.00 |
| May 19, 2026 | SHERMAN JEFFREY | A | $0.00 |
| May 19, 2026 | LEFF JONATHAN | A | $0.00 |
Reddit Sentiment
69°
Warm
Bearish
Neutral
Bullish
50 institutional holders with $113.5M total value (25,241,455 shares) as of 2026-Q1. Top holders: BlackRock,, DRIEHAUS, VANGUARD. Net buying activity: 18 institutions added/increased vs 8 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3,752,200 | $16.9M | 14.9% | — |
| 2 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2,934,399 | $13.2M | 11.6% | DOUBLED +448.0% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2,866,349 | $12.9M | 11.4% | — |
| 4 | GOLDMAN SACHS GROUP INC | 1,561,585 | $7.0M | 6.2% | — |
| 5 | RTW INVESTMENTS, LP | 1,500,000 | $6.8M | 5.9% | TRIM -52.0% |
| 6 | Woodline Partners LP | 1,400,850 | $6.3M | 5.6% | ADD +74.9% |
| 7 | Point72 Asset Management, L.P. | 1,047,385 | $4.7M | 4.2% | TRIM -28.3% |
| 8 | MARSHALL WACE, LLP | 933,464 | $4.2M | 3.7% | — |
| 9 | STATE STREET CORP | 911,326 | $4.1M | 3.6% | — |
| 10 | DIMENSIONAL FUND ADVISORS LP | 798,462 | $3.6M | 3.2% | DOUBLED +143.8% |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 739,942 | $3.3M | 2.9% | DOUBLED +148.9% |
| 12 | Nuveen, LLC | 674,915 | $3.0M | 2.7% | DOUBLED +541.7% |
| 13 | Alyeska Investment Group, L.P. | 617,211 | $2.8M | 2.4% | TRIM -33.5% |
| 14 | D. E. Shaw & Co., Inc. | 575,624 | $2.6M | 2.3% | — |
| 15 | CITADEL ADVISORS LLC | 519,132 | $2.3M | 2.1% | — |
| 16 | TWO SIGMA INVESTMENTS, LP | 475,612 | $2.1M | 1.9% | DOUBLED +119.1% |
| 17 | MORGAN STANLEY | 420,813 | $1.9M | 1.7% | DOUBLED +209.5% |
| 18 | VANGUARD PORTFOLIO MANAGEMENT LLC | 406,558 | $1.8M | 1.6% | — |
| 19 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 300,000 | $1.4M | 1.2% | — |
| 20 | Hudson Bay Capital Management LP | 292,250 | $1.3M | 1.2% | ADD +76.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| DRIEHAUS CAPITAL MANAGEMENT LLC | DOUBLED | 535,464 | 2,934,399 | +448.0% | $13.2M | 2026-Q1 |
| RTW INVESTMENTS, LP | TRIM | 3,125,000 | 1,500,000 | -52.0% | $6.8M | 2026-Q1 |
| Woodline Partners LP | ADD | 800,850 | 1,400,850 | +74.9% | $6.3M | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 1,461,028 | 1,047,385 | -28.3% | $4.7M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 327,494 | 798,462 | +143.8% | $3.6M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 297,266 | 739,942 | +148.9% | $3.3M | 2026-Q1 |
| Nuveen, LLC | DOUBLED | 105,182 | 674,915 | +541.7% | $3.0M | 2026-Q1 |
| Alyeska Investment Group, L.P. | TRIM | 927,821 | 617,211 | -33.5% | $2.8M | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 135,983 | 420,813 | +209.5% | $1.9M | 2026-Q1 |
| DEUTSCHE BANK AG\ | DOUBLED | 34,390 | 93,132 | +170.8% | $419.1K | 2026-Q1 |
| Marex Group plc | TRIM | 312,000 | 82,000 | -73.7% | $369.0K | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 21,070 | 69,087 | +227.9% | $310.9K | 2026-Q1 |
| CWM, LLC | ADD | 32,631 | 64,126 | +96.5% | $288.6K | 2026-Q1 |
| FMR LLC | DOUBLED | 12,880 | 63,570 | +393.6% | $286.1K | 2026-Q1 |
| FEDERATED HERMES, INC. | NEAR_EXIT | 358,907 | 61,350 | -82.9% | $276.1K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | TRIM | 94,000 | 59,700 | -36.5% | $268.6K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | DOUBLED | 15,614 | 32,799 | +110.1% | $157.1K | 2026-Q1 |
| MetLife Investment Management, LLC | ADD | 13,597 | 26,668 | +96.1% | $120.0K | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEAR_EXIT | 344,246 | 26,445 | -92.3% | $119.0K | 2026-Q1 |
| STRS OHIO | DOUBLED | 7,900 | 21,700 | +174.7% | $97.7K | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 10,573 | 16,336 | +54.5% | $73.5K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | DOUBLED | 1,638 | 6,903 | +321.4% | $31.1K | 2026-Q1 |
| Mirae Asset Global Investments Co., Ltd. | ADD | 4,159 | 5,664 | +36.2% | $25.5K | 2026-Q1 |
| Russell Investments Group, Ltd. | TRIM | 5,917 | 3,589 | -39.3% | $16.2K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 148 | 1,959 | +1223.6% | $8.8K | 2026-Q1 |
6 unique insiders with 10 transactions. Net insider value: $6.0M ($6.0M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 19, 2026 | THOMAS FRANK E | Director | AWARD | 55,150 | — | — |
| May 19, 2026 | Hamilton Thomas Edward | Director | AWARD | 55,150 | — | — |
| May 19, 2026 | Truitt Joseph | Director | AWARD | 55,150 | — | — |
| May 19, 2026 | SHERMAN JEFFREY W | Director | AWARD | 55,150 | — | — |
| May 19, 2026 | LEFF JONATHAN S | Director | AWARD | 55,150 | — | — |
| May 19, 2026 | Flynn James E | Director | AWARD | 55,150 | — | — |
| Feb 27, 2026 | SHERMAN JEFFREY W | Director | BUY | 5,000 | $5.00 | $25.0K |
| Feb 27, 2026 | THOMAS FRANK E | Director | BUY | 5,000 | $5.00 | $25.0K |
| Feb 27, 2026 | Flynn James E | Director | BUY | 1,084,010 | $5.00 | $5.4M |
| Feb 27, 2026 | Hamilton Thomas Edward | Director | BUY | 100,000 | $5.00 | $500.0K |
5 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 6.6/10.
BULLISH
8-K
7/10
Larimar Therapeutics reported Q1 2026 net loss of $29.6M ($0.31/share), roughly in line with the $29
May 14, 2026
BULLISH
PRESS-RELEASE
7/10
Larimar Therapeutics reported Q1 2026 EPS of -$0.31, beating consensus of -$0.57 by 45.6%, with no r
May 14, 2026
BULLISH
CLUSTER
8/10
Four insiders at Larimar Therapeutics collectively purchased $6.07 million in shares over a single d
Mar 3, 2026
BULLISH
CLUSTER
6/10
Three insiders at Larimar Therapeutics collectively purchased $550,000 worth of shares in open-marke
Mar 2, 2026
NEUTRAL
8-K
5/10
Larimar Therapeutics is conducting a follow-on public offering of 20 million shares at $5.00 per sha
Feb 27, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 8 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$15.11 mean target
+344.4% upside
Strong Buy (3.00)
$7.00 Low
$26.00 High
| Metric | Value |
|---|---|
| Current Price | $3.40 |
| Target Low | $7.00 |
| Target Mean | $15.11 |
| Target Median | $13.00 |
| Target High | $26.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.38 | $-0.48 | $-0.34 | 6.7% | +17.2% | 1↑ 0↓ | $0.0B | 0.0% | 6 |
| Next Q 2026-09-30 |
$-0.43 | $-0.51 | $-0.35 | 29.5% | +4.0% | 1↑ 0↓ | $0.0B | 0.0% | 6 |
| Current FY 2026-12-31 |
$-1.62 | $-1.82 | $-1.43 | 28.7% | +23.4% | 2↑ 0↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-12-31 |
$-1.23 | $-2.35 | $-0.16 | 24.3% | +25.7% | 1↑ 0↓ | $0.1B | 0.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.383 | |
| 7d ago | $-0.388 | +0.005 |
| 30d ago | $-0.462 | +0.079 |
| 60d ago | $-0.525 | +0.142 |
| 90d ago | $-0.422 | +0.040 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | JP Morgan | INITIATE | — | Overweight |
| May 18, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 20, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 3, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Feb 25, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | Wedbush | REITERATE | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 7 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 9 | 7 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 9 | 7 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 9 | 7 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 9 | 7 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 9 | 7 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
69°
Warm
Bearish
Neutral
Bullish
4 mentions
3 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 25, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| Feb 24, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Next penny stock to go up 10-20x in a few days
▲ 48
💬 22
⚡ 3.2
Here is the next stock to 10-20x - $LRMR
▲ 1
💬 6
⚡ 0.0
Here is the next stock to 10-20x - $LRMR
▲ 1
💬 0
⚡ 0.0
Time for another Biotech - LRMR
▲ 23
💬 19
⚡ 0.9
Jun 10, 2026
short_volume
Short Volume: LRMR — 57.6% short (0.6M / 1.1M)
Short: 629,783 | Exempt: 8,000 | TRF Vol: 1,093,669 | Short Ratio: 57.6% | Off-exchange volume (dark pool + OTC)
May 14, 2026
earnings
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
<p align="justify">BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechn
May 7, 2026
earnings_calendar
LRMR Q1 2026 Earnings After Market Close — 2026-05-07
Apr 28, 2026
earnings_calendar
LRMR Q1 2026 Earnings After Market Close — 2026-04-28
Mar 19, 2026
earnings
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
<p><em>*</em><em>Pro forma cash, cash equivalents, and marketable securities of $244.5 million reflects $136.9 million of cash, cash equivalents and m
Mar 18, 2026
earnings_calendar
LRMR Q4 2025 Earnings After Market Close — 2026-03-18
Mar 4, 2026
other
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
<p align="justify">BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotec